Background: Sorafenib has recently been shown to reduce tumour growth in
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …

Background Multidrug resistance is a major reason for poor treatment results in advanced
hepatoblastoma (HB). Several alternative treatment options are currently under investigation …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Objective To investigate the inhibitory effect of sorafenib in combination with cisplatin (DDP)
on the proliferation of hepatocellular carcinoma cells and explore the molecular …

Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Sorafenib (Nexavar®) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …

Background/Aim: Sorafenib is currently the only medical treatment with proven efficacy
against hepatocellular carcinoma (HCC). HCC cell lines display heterogeneous sensitivity to …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …

Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas
some patients have suboptimal response to sorafenib. We aimed to evaluate the association …